BNF:

11.4.1

Status:

Red

Decision Date:

August 2011

Comments

RED:

• NICE TA229: recommended for specified people with macular oedema secondary to retinal vein occlusion.  (Decision date - August 2011).
• NICE TA349: for diabetic macular oedema.  (Decision date - August 2015).
• NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis.  (Decision date - August 2017).
• NICE TA824: Dexamethasone intravitreal implant (Ozurdex) for treating diabetic macular oedema.  (Decision date - October 2022).

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
• 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again